SymBio Pharmaceuticals Limited announced that it has entered into a purchase agreement to issue 1,000,000 common shares at issue price of ¥662 per share for gross proceeds of ¥662,000,000 and 20,000 58th stock acquisition rights at issue price of ¥688 per unit for gross proceeds of ¥13,760,000; for an aggregate gross proceeds of ¥675,760,000? on May 16, 2022. The transaction will include participation from CVI Investments, Inc. The transaction is expected to close on June 1, 2022.

The exercise price of stock acquisition right is ¥785. The exercise price for the rights is from June 2, 2022 to June 1, 2027. The company will issue securities in third party allotment.

The transaction has been approved by the board of directors of the company.